A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
Inclusion criteria:
Exclusion criteria:
CABA, Buenos Aires C1430EGF, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
Sofia, 1606, Bulgaria
Ostrava-Poruba, 708 52, Czechia
Aalborg, North Denmark 9000, Denmark
Tbilisi, 0112, Georgia
Bonn, Rhineland-Palatinate 53123, Germany
Kiel, Schleswig-Holstein 24105, Germany
Békéscsaba, 5600, Hungary
Hyderabad, Andhra Pradesh 500032, India
Vilnius, LT-08661, Lithuania
Chisinau, MD-2025, Moldova
Chisinau, MD-2068, Moldova
Wroclaw, 144-148, Poland
Nizhny Novgorod, 603126, Russia
Penza, 440026, Russia
Saint Petersburg, 195067, Russia
Samara, 443011, Russia
Junggu, Daegu 41944, South Korea
Bangkoknoi, Bangkok 10700, Thailand
Ivano-Frankivsk, 76018, Ukraine
Ivano-Frankivsk, 76018, Ukraine
Kharkiv, 61058, Ukraine
Kharkiv, 61124, Ukraine
Kherson, 73000, Ukraine
Lviv, 79059, Ukraine
Odesa, 65025, Ukraine
Vinnytsia, 21009, Ukraine
Vinnytsia, 21029, Ukraine
Zaporizhzhya, 69035, Ukraine
London, Greater London E11 1NR, United Kingdom
Norwich, Norfolk NR4 7UQ, United Kingdom